RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation in treating patients who have hematologic cancer or aplastic anemia.

Condition	Treatment or Intervention	Phase
childhood Hodgkin's lymphoma childhood non-Hodgkin's lymphoma Gastrointestinal Cancer hematopoietic and lymphoid cancer	Drug: anti-thymocyte globulin  Drug: cyclophosphamide  Drug: fludarabine  Procedure: biological response modifier therapy  Procedure: bone marrow ablation with stem cell support  Procedure: chemotherapy  Procedure: graft versus tumor induction  Procedure: non-specific immune-modulator therapy  Procedure: peripheral blood stem cell transplantation	Phase II

Further Study Details: 

OBJECTIVES:

• Determine the rates of durable full donor hematologic engraftment in patients with high-risk hematologic malignancies or severe aplastic anemia treated with non-myeloablative conditioning using fludarabine, cyclophosphamide, and anti-thymocyte globulin followed by allogeneic peripheral blood stem cell transplantation.
• Determine the acute and delayed toxic effects of this non-myeloablative conditioning regimen in this patient population.
• Determine the event-free and overall survival of patients treated with this regimen.
• Determine the incidence and severity of acute and chronic graft-versus-host disease in patients treated with this regimen.
• Determine the rate and quality of immune reconstitution in patients treated with this regimen.
• Determine the rate of disease relapse and incidence of post-transplantation lymphoproliferative disease in these patients.

OUTLINE: Patients are stratified according to disease category (malignant vs non-malignant) and graft source (unrelated vs HLA-matched sibling).

Beginning at least 4 weeks after conventional-dose chemotherapy, patients receive non-myeloablative conditioning comprising fludarabine IV over 30 minutes on days -8 to -4, cyclophosphamide IV over 2 hours on days -3 to -2, and anti-thymocyte globulin IV over at least 4 hours on days -2 and -1. Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.

Patients are followed weekly for 3 months, every 2 weeks for 3 months, monthly for 6 months, and then every 2 months thereafter.

PROJECTED ACCRUAL: A minimum of 30 patients will be accrued for this study within 4 years.

Ages Eligible for Study:  up to  70 Years,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

• Histologically proven high-risk hematologic malignancy
• Acute non-lymphocytic leukemia (ANLL) after induction failure, or in first complete remission (CR) with high-risk features, including any of the following:
• Stem cell or biphenotypic classification (AML-M0)
• Erythroleukemia (AML-M6)
• Acute megakaryocytic leukemia (AML-M7)
• Cytogenetic markers indicative of poor prognosis
• Failure to achieve CR after standard induction therapy
• Acute lymphocytic leukemia (ALL) or ANLL in relapse or second or subsequent remission
• Chronic myelogenous leukemia (CML) in chronic or accelerated phase
• Patients with CML in blast crisis are eligible after reinduction chemotherapy places them in chronic phase
• High-risk ALL in first CR with high risk defined by presence of t(4;11), t(9;22) translocation, hyperleukocytosis (initial WBC greater than 30,000/mm
• ), or failure to achieve CR by day 28 after standard induction
• No T-cell ALL or t(8;14) positive B-cell ALL in first remission with hyperleukocytosis
• Myelodysplastic syndrome by peripheral blood smear and bone marrow examination
• Refractory to medical management OR
• Cytogenetic abnormalities predictive of transformation into acute leukemia including 5q-, 7q-, monosomy 7, and trisomy 8 OR
• Evidence of evolution to AML (e.g., refractory anemia with excess blasts (RAEB) or RAEB in transformation)
• Multiple myeloma, non-Hodgkin's lymphoma (NHL), ANLL, or ALL with recurrent disease after autologous stem cell transplantation (SCT)
• At least 3 months since prior autologous SCT
• Hodgkin's lymphoma, NHL, or multiple myeloma beyond first CR or primary induction failures whose disease has demonstrated sensitivity to pre-transplantation cytoreduction (defined as greater than 50% reduction in tumor burden)
• Mantle zone NHL allowed after induction therapy
• Myeloproliferative disorder that is non-responsive to medical management and requires allografting, unless evidence of grade 3 or worse myelofibrosis on marrow biopsy OR
• Histologically proven acquired severe aplastic anemia (SAA) that is recurrent or unresponsive after anti-thymocyte globulin and/or cyclosporine
• SAA defined by at least 2 of the following conditions:
• Granulocyte count less than 500/mm^3
• Platelet count less than 20,000/mm^3
• Absolute reticulocyte count less than 20,000/mm^3 after correction for hematocrit
• Ineligible for full ablative conditioning due to any of the following conditions:
• Prior extensive therapy (more than 2 salvage chemotherapy regimens and/or autologous transplantation)
• Over age 55 OR
• Under age 55 with comorbid disease (e.g., suboptimal cardiac, pulmonary, or renal function and/or prior life-threatening infection)
• HLA-A, B, and DR phenotypically identical sibling donor OR
• HLA-A, B, and DR identical genetically matched unrelated donor
• No ANLL in first CR (less than 5% blasts in marrow) with translocations t(8;21) and inv(16) unless failed first-line induction therapy OR
• No ANLL in first CR (less than 5% blasts in marrow) with translocations t(15;17) abnormality unless failed first-line induction therapy OR molecular evidence of persistent disease
• No active CNS disease

PATIENT CHARACTERISTICS: Age:

• 0 to 70

Performance status:

• Zubrod 0-1
• Karnofsky 80-100%

Life expectancy:

• At least 3 months

Hematopoietic:

• See Disease Characteristics

Hepatic:

• ALT/AST no greater than 4 times normal
• Bilirubin no greater than 2.0 mg/dL

Renal:

• See Disease Characteristics
• Creatinine clearance at least 50 mL/min

Cardiovascular:

• See Disease Characteristics
• Shortening fraction or ejection fraction at least 40% of normal for age by echocardiogram or radionuclide scan
• No clinically significant comorbid illnesses (e.g., myocardial infarction or cerebrovascular accident)

Pulmonary:

• See Disease Characteristics
• FVC and FEV_1 at least 60% of predicted for age
• DLCO at least 60% of predicted for adults

Other:

• No severe neurosensory symptoms (i.e., peripheral neuropathy)
• HIV negative
• Active infection allowed if controlled by appropriate drug therapy
• Not pregnant or nursing
• Negative pregnancy test

PRIOR CONCURRENT THERAPY: Biologic therapy:

• See Disease Characteristics

Chemotherapy:

• See Disease Characteristics

Endocrine therapy:

• Not specified

Radiotherapy:

• Not specified

Surgery:

• Not specified

Other:

• Recovered from prior therapy
• No concurrent investigational agents unless approved by protocol investigators

Ohio
      Ireland Cancer Center, Cleveland,  Ohio,  44106-5065,  United States

Study chairs or principal investigators

Mary J. Laughlin, MD,  Study Chair,  Ireland Cancer Center   

Study ID Numbers:  CDR0000068253; CWRU-3Y00; CWRU-050007; NCI-G00-1868
Record last reviewed:  September 2004
Last Updated:  October 13, 2004
Record first received:  October 4, 2000
ClinicalTrials.gov Identifier:  NCT00006379
Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2005-04-08